Novartis/Celgene Ritadex "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Dexmethylphenidate HCl, a single-isomer version of Novartis' Ritalin, is "approvable" Aug. 21 for symptoms of attention deficit hyperactivity disorder. Celgene and Novartis expect approval of Ritadex by the first week of October. Novartis will market the drug
You may also be interested in...
Efforts are underway to create a harmonized approach among Persons Responsible for Regulatory Compliance who play a pivotal role in meeting the requirements of the EU MDR and IVDR. And liability issues are high on the agenda.
Legal experts explain why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Ex-Novartis executive and co-founder of investment bank MM Dillon & Co shares insights around where healthcare unicorns can be found and some core criteria to build such firms.